Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring
Authors' conclusion
In conclusion, the MiniMed 780G AHCL system enables the safe achievement of recommended glycemic targets in people with T1D after 6 months of use.
Study context
- Population
- People with T1D previously treated with CSII and flash glucose monitoring; mean age 41 ± 13.6 years, 60% females, diabetes duration 28 ± 11 years
- Participants
- 47 people
- Comparison
- MiniMed 780G advanced hybrid closed-loop (AHCL) after 6 months vs baseline
- Outcome
- TIR 70-180 mg/dL
- Follow-up
- 6 months
Methodological detailsreal-life setting, single-group
- Real-life setting
- Single-group
Main finding
As reported in the abstract
Further findings
Time >180 mg/dL · baseline to 6 months
- Time in hyperglycemia >180 mg/dL decreased from baseline to 6 months
- 26.6% to 19.3%
CV · baseline to 6 months
- CV decreased from baseline to 6 months
- 36% to 31.6%
Safety
Time <70 mg/dL · baseline to 6 months
- Time in hypoglycemia <70 mg/dL decreased from baseline to 6 months
- 4.6% to 2.3%
Severe hypoglycemia, DKA, diabetes-related hospital admissions
- Episodes of severe hypoglycemia, DKA or diabetes-related hospital admissions
- 0
Original publication
Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring. Diabetes Technol Ther. Published 23 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →